Therapeutic potential of nicorandil beyond anti-anginal drug: A review on current and future perspectives

Heliyon. 2024 Mar 31;10(7):e28922. doi: 10.1016/j.heliyon.2024.e28922. eCollection 2024 Apr 15.

Abstract

Nicorandil (NIC) is a well-known anti-anginal agent, which has been recommended as one of the second-line treatments for chronic stable angina as justified by the European guidelines. It shows an efficacy equivalent to that of classic anti-anginal agents. NIC has also been used clinically in various cardiovascular diseases such as variant or unstable angina and reperfusion-induced damage following coronary angioplasty or thrombolysis. Different mechanisms have been involved in the protective effects of nicorandil in various diseases, including opening of adenosine triphosphate-sensitive potassium (KATP) channel and donation of nitric oxide (NO). In recent years, NIC has been found to show numerous pharmacological activities such as neuroprotective, nephroprotective, hepatoprotective, cardioprotective, and testicular protective effects, among other beneficial effects on the body. The present review dwells on the pharmacological potentials of NIC beyond its anti-anginal action.

Keywords: Cardioprotective; Gastric ulcer; Inflammation; Nicorandil; Renal protection.

Publication types

  • Review